How have ALIOF shares performed in 2023?

ALIOF's stock was trading at $278.50 at the beginning of 2023. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50. View the best growth stocks for 2023 here .

How were ALIOF's earnings last quarter?

ALIOF (OTCMKTS:ALIOF) posted its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million.

How do I buy shares of ALIOF?

Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ALIOF Stock Price, News & Analysis (OTCMKTS:ALIOF)

$278.50

0.00 (0.00%)

(As of 09/27/2022)

Compare

Today's Range: $278.50
▼
$278.50
50-Day Range: $278.50
▼
$278.50
52-Week Range: $138.01
▼
$286.30

Volume: N/A
Average Volume: 924 shs
Market Capitalization: $29.89 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About ALIOF Stock (OTCMKTS:ALIOF)

Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.

ALIOF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALIOF Stock News Headlines

August 24, 2023 | thestreet.com

5 Things You Must Know Before the Market Opens Friday

May 5, 2023 | msn.com

India goes Digital: 5 major indicators of MASSIVE transformation

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

April 14, 2021 | reuters.com

4th Circuit revives antitrust claims against Actelion over Tracleer pricing

March 23, 2021 | theguardian.com

'What appointments did these dogs have to keep?': long lunches and brief liaisons in a radical new dogumentary

December 12, 2020 | msn.com

College Student Arrested in Delhi for Abducting Minor Girl After Befriending Her on Facebook

July 23, 2020 | sg.finance.yahoo.com

Synthetic Biologics Inc. (SYN) Looks Strong as Stock Gains 34.3%

July 23, 2020 | sg.finance.yahoo.com

Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46%

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

January 17, 2019 | www.marketwatch.com

Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application

See More Headlines

Receive ALIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/16/2015
Today: 12/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Medicinals & Botanicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ALIOF
CUSIP: N/A
CIK: N/A
Web: www.actelion.com
Phone: (161) 565-6565
Fax: 41-61-565-6500
Employees: N/A
Year Founded: 1997

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 107,330,000
Free Float: N/A
Market Cap: $29.89 billion
Optionable: Not Optionable
Beta: N/A

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Nicholas Franco
Chief Business Development Officer & EVP

Key Competitors

View All Competitors

Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ALIOF was last updated on Sunday, December 3, 2023 at 4:59 PM.

Pros

Here are some ways that investors could benefit from investing in ALIOF:

Recent developments in ALIOF have shown positive growth potential, indicating a promising future for the company.
ALIOF's latest product, the ALIOF X, has received positive reviews and is expected to drive sales and revenue.
ALIOF's stock price has been steadily increasing over the past year, providing potential for capital appreciation.
ALIOF has a strong financial position with a healthy balance sheet and positive cash flow, reducing the risk of financial instability.
ALIOF has a diversified product portfolio, reducing reliance on any single product and providing stability in revenue streams.

Cons

Investors should be bearish about investing in ALIOF for these reasons:

The competitive landscape in the industry is intense, with several well-established players, which may pose challenges for ALIOF's market share.
ALIOF's latest financial reports show a decline in profitability, raising concerns about the company's ability to generate sustainable earnings.
The global economic uncertainty and potential market volatility may impact ALIOF's sales and revenue growth.
ALIOF's heavy reliance on a single market or region exposes it to geopolitical risks and regulatory changes that could negatively impact its operations.
ALIOF's high debt levels may limit its flexibility in pursuing growth opportunities and increase its vulnerability to interest rate fluctuations.

ALIOF Stock Analysis - Frequently Asked Questions

How have ALIOF shares performed in 2023?: ALIOF's stock was trading at $278.50 at the beginning of 2023. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50.
View the best growth stocks for 2023 here.
How were ALIOF's earnings last quarter?: ALIOF (OTCMKTS:ALIOF) posted its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million.
How do I buy shares of ALIOF?: Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:ALIOF) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial